News Biogen Inc. Sao Paulo

Equities

BIIB34

BRBIIBBDR001

Market Closed - Sao Paulo Other stock markets 10:37:11 2024-07-10 am EDT			5-day change	1st Jan Change
206.5 ^BRL	+0.24%		+0.24%	+0.63%

Jul. 16	Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says	MT
Jul. 16	Redburn Atlantic Adjusts Price Target on Biogen to $230 From $235, Maintains Neutral Rating	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says	Jul. 16	MT
Redburn Atlantic Adjusts Price Target on Biogen to $230 From $235, Maintains Neutral Rating	Jul. 16	MT
Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating	Jul. 16	MT
Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB	Jul. 16	PR
Novo owner backs Swiss biotech Asceneuron in $100 million round	Jul. 16	RE
Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline	Jul. 15	PR
July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB	Jul. 15	PR
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease	Jul. 12	MT
Eisai Co., Ltd. - LEQEMBI, Approved for the Treatment of Alzheimer's disease in Israel	Jul. 12	AQ
Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating	Jul. 12	MT
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB	Jul. 12	PR
BIIB Investors Have Opportunity to Join Biogen Inc. Securities Fraud Investigation with the Schall Law Firm	Jul. 11	BU
Eisai Co., Ltd. - LEQEMBI Approved for the Treatment of Alzheimer's disease in Hong Kong	Jul. 11	AQ
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331	Jul. 11	MT
Biogen, Eisai Say Alzheimer's Drug Leqembi Secures Regulatory Approval in Hong Kong	Jul. 11	MT
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit	Jul. 10	PR
Biogen Inc. Sued for Securities Law Violations - Contact the Schall Law Firm to Discuss Your Legal Rights BIIB	Jul. 10	PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB	Jul. 10	PR
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen	Jul. 10	PR
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB	Jul. 09	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biogen Inc. Sao Paulo

Equities

BIIB34

BRBIIBBDR001

Summary

Filters